CoChat

IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis

Brooks, Gavin D., McLeod, Louise, Alhayyani, Sultan, Miller, Alistair, Russell, Prudence A., Ferlin, Walter, Rose-John, Stefan, Ruwanpura, Saleela, Jenkins, Brendan J. · 2016 · Cancer Research
Cited by 119

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Oncogenic KRAS mutations occur frequently in lung adenocarcinoma. The signaling pathways activated by IL6 promote Kras-driven lung tumorigenesis, but the basis for this cooperation is uncertain. In this study, we used the gp130F/F (Il6st) knock-in mouse model to examine the pathogenic contribution of hyperactivation of the STAT3 arm of IL6 signaling on KRAS-driven lung tumorigenesis. Malignant growths in the gp130F/F:KrasG12D model displayed features of atypical adenomatous hyperplasia, adenocarcinoma in situ, and invasive adenocarcinoma throughout the lung, as compared with parental KrasG12D mice, where STAT3 was not hyperactivated. Among IL6 family cytokines, only IL6 was upregulated in the lung. Accordingly, normalization of pulmonary STAT3 activity, by genetic ablation of either Il6 or Stat3, suppressed the extent of lung cancer in the model. Mechanistic investigations revealed elevation in the lung of soluble IL6 receptor (sIL6R), the key driver of IL6 trans-signaling, and blocking this mechanism via interventions with an anti-IL6R antibody or the inhibitor sgp130Fc ameliorated lung cancer pathogenesis. Clinically, expression of IL6 and sIL6R was increased significantly in human specimens of lung adenocarcinoma or patient serum. Our results offer a preclinical rationale to clinically evaluate IL6 trans-signaling as a therapeutic target for the treatment of KRAS-driven lung adenocarcinoma. Cancer Res; 76(4); 866–76. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-2388

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 119

Metadata

Authors
Brooks, G. D., McLeod, L., Alhayyani, S., Miller, A., Russell, P. A., Ferlin, W., Rose-John, S., Ruwanpura, S., & Jenkins, B. J.
Venue
Cancer Research
Published
2016-02-14
Volume
76
Issue
4
Pages
866-876
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2226127569
Cited by
119
References
12
FWCI
7.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2388
The paper
Brooks, G. D., McLeod, L., Alhayyani, S., Miller, A., Russell, P. A., Ferlin, W., Rose-John, S., Ruwanpura, S., & Jenkins, B. J. (2016). IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2388

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.